The world is entering a new era of vaccines. Following the success of COVID-19 mRNA shots, scientists have a far greater capacity to tailor shots to a virus’s structure, putting a host of new vaccines on the horizon. These shots are welcome since RSV can be dangerous, even deadly, in the very old and very young. But the shots are also expensive. So their advent is forcing the United States to face anew questions it has long sidestepped: How much should an immunization that will possibly be given — maybe yearly — to millions of Americans cost to be truly valuable? Continue reading A new era of vaccines leaves old questions about prices unanswered